Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
Neurocrine Biosciences (NBIX) has scheduled its first quarter 2025 financial results conference call and webcast for May 5, 2025, at 1:30 p.m. Pacific Time. The company will release its Q1 2025 financial results via press release at 1:00 p.m. PT on the same day.
Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for various conditions including tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company maintains a pipeline of compounds in mid- to late-phase clinical development across its core therapeutic areas.
Neurocrine Biosciences (NBIX) ha programmato la conference call e il webcast per la presentazione dei risultati finanziari del primo trimestre 2025 il 5 maggio 2025 alle 13:30 ora del Pacifico. La società pubblicherà i risultati finanziari del primo trimestre 2025 tramite comunicato stampa alle 13:00 PT dello stesso giorno.
Neurocrine Biosciences è un'azienda biofarmaceutica specializzata in neuroscienze, con trattamenti approvati dalla FDA per diverse patologie, tra cui discinesia tardiva, corea di Huntington, iperplasia surrenalica congenita, endometriosi e fibromi uterini. L'azienda dispone di un portafoglio di composti in fase clinica da media a avanzata nei suoi principali ambiti terapeutici.
Neurocrine Biosciences (NBIX) ha programado su llamada y webcast para presentar los resultados financieros del primer trimestre de 2025 el 5 de mayo de 2025 a la 1:30 p.m., hora del Pacífico. La compañía publicará sus resultados financieros del primer trimestre de 2025 mediante un comunicado de prensa a la 1:00 p.m. PT del mismo día.
Neurocrine Biosciences es una empresa biofarmacéutica enfocada en neurociencia, con tratamientos aprobados por la FDA para diversas condiciones, incluyendo discinesia tardía, corea de Huntington, hiperplasia suprarrenal congénita, endometriosis y fibromas uterinos. La compañía cuenta con un portafolio de compuestos en desarrollo clínico de fase media a avanzada en sus áreas terapéuticas principales.
Neurocrine Biosciences (NBIX)는 2025년 5월 5일 오후 1시 30분(태평양 표준시)에 2025년 1분기 재무실적 컨퍼런스 콜 및 웹캐스트를 예정하고 있습니다. 회사는 같은 날 오후 1시(태평양 표준시)에 보도자료를 통해 2025년 1분기 재무실적을 발표할 예정입니다.
Neurocrine Biosciences는 신경과학에 중점을 둔 바이오제약 회사로, 지연성 운동장애, 헌팅턴 무도병, 선천성 부신 과형성증, 자궁내막증, 자궁근종 등 다양한 질환에 대해 FDA 승인 치료제를 보유하고 있습니다. 회사는 핵심 치료 분야에서 중기에서 후기 임상 개발 단계에 있는 여러 화합물 파이프라인을 유지하고 있습니다.
Neurocrine Biosciences (NBIX) a programmé sa conférence téléphonique et son webcast sur les résultats financiers du premier trimestre 2025 pour le 5 mai 2025 à 13h30, heure du Pacifique. La société publiera ses résultats financiers du premier trimestre 2025 par communiqué de presse à 13h00 PT le même jour.
Neurocrine Biosciences est une entreprise biopharmaceutique spécialisée en neurosciences, disposant de traitements approuvés par la FDA pour diverses pathologies, notamment la dyskinésie tardive, la chorée de Huntington, l'hyperplasie congénitale des surrénales, l'endométriose et les fibromes utérins. L'entreprise possède un portefeuille de composés en développement clinique de phase intermédiaire à avancée dans ses principaux domaines thérapeutiques.
Neurocrine Biosciences (NBIX) hat seine Telefonkonferenz und Webcast zur Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für den 5. Mai 2025 um 13:30 Uhr Pazifischer Zeit angesetzt. Das Unternehmen wird die Finanzergebnisse für das erste Quartal 2025 am selben Tag um 13:00 Uhr PT per Pressemitteilung veröffentlichen.
Neurocrine Biosciences ist ein biopharmazeutisches Unternehmen mit Schwerpunkt Neurowissenschaften und verfügt über von der FDA zugelassene Behandlungen für verschiedene Erkrankungen, darunter tardive Dyskinesie, Huntington-Chorea, kongenitale adrenale Hyperplasie, Endometriose und Uterusmyome. Das Unternehmen verfügt über eine Pipeline von Wirkstoffen in der klinischen Entwicklung von der Mittel- bis zur Spätphase in seinen Kerntherapiegebieten.
- None.
- None.
Conference Call and Webcast Scheduled for Monday, May 5
The schedule for the press release and conference call / webcast is as follows:
- Q1 2025 Press Release: May 5, 2025 at 1:00 p.m. PT / 4:00 p.m. ET
- Q1 2025 Conference Call: May 5, 2025 at 1:30 p.m. PT / 4:30 p.m. ET
- Domestic Dial-In Number: 800-245-3047
- International Dial-In Number: 203-518-9765
- Conference ID: NBIX
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook.
(*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2025-financial-results-302427961.html
SOURCE Neurocrine Biosciences, Inc.
FAQ
When will Neurocrine Biosciences (NBIX) release its Q1 2025 earnings?
How can investors access NBIX's Q1 2025 earnings call?
What therapeutic areas does NBIX currently have FDA-approved treatments for?
How long will NBIX's Q1 2025 earnings webcast be available for replay?
